A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment

NCT01994057 · clinicaltrials.gov ↗

RECRUITING

Status

1000

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer (NSCLC)
EGFR-TKI Resistant Mutation
EGFR-TKI Sensitizing Mutation
Germline Mutations
Somatic Mutation

Sponsor

Sun Yat-sen University